AI-generated analysis. Always verify with the original filing.
MBX Biosciences announced completion of an End-of-Phase 2 meeting with the FDA and plans to initiate a Phase 3 trial for once-weekly canvuparatide for chronic hypoparathyroidism in Q3 2026. The trial will enroll approximately 160 patients in a 3:1 randomization to canvuparatide or placebo, with primary endpoint of normal serum calcium and independence from conventional therapy at week 26.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Ac
Other Events. On March 9, 2026, the Company announced completion of an End-of-Phase 2 ("EOP2") meeting with the U.S. Food and Drug Administration ("FDA"). Based
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Issued by MBX Biosciences, Inc. on March 9, 2026 104 Cover Page Inte